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The autogenous saphenous vein is considered the best bypass graft material for arterial bypasses below the inguinal ligament.
However, a synthetic graft or prosthesis is considered an acceptable alternative, especially when the distal anastomosis is
situated above the knee. Some studies even suggest that patency rates for vein and synthetic grafts are comparable, whereas
others indicate that a vein graft is superior to a prosthetic graft, even above the knee.
To test the hypothesis that both vein grafts and synthetic prostheses are equally beneficial in the above-knee position, we
performed a systematic review of available studies comparing the patency of saphenous vein and polytetrafluoroethylene
(PTFE) as bypass material. English and German medical literature from 1966 to 2002 was searched using Medline, and 25
articles meeting our inclusion and exclusion criteria were selected.
The patency of venous bypasses was superior to that of PTFE bypasses at all time intervals studied. After 2 years, the
primary patency rate of venous bypasses was 81% as compared to 67% for PTFE bypasses, and after 5 years it was 69 and
49%, respectively. After 5 years, the secondary patency of PTFE bypasses reached 60%. When only randomized trials were
considered, venous bypasses were again superior to PTFE bypasses at all intervals studied. After 2 years, the primary
patency rate of venous and PTFE bypasses was 80 and 69%, respectively, and after 5 years it was 74 and 39%, respectively.
Since both randomized and retrospective studies comparing venous with PTFE bypasses showed that vein grafts were
‘better’ than PTFE prostheses, the null hypothesis that there is no difference between the two types of graft material was
rejected (p ¼ 0.008).
We conclude from this systematic review that if a saphenous vein is available, a venous bypass should be chosen at all times,
even if patients have an anticipated short life expectancy (,2 years). If the saphenous vein is absent or not suitable for bypass
grafting, PTFE is a good alternative as bypass material.
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Introduction
Since Kunlin performed the first bypass with an
autologous saphenous vein in 1949, bypass grafting
has proved to be an effective form of treatment for
peripheral arterial occlusive disease.1 Many studies
have sought to determine the best material and
technique for revascularization of the lower extremi-
ties in obstructive arterial disease. The saphenous vein
is considered to be the gold standard for bypasses with
a distal anastomosis below the knee.2 For the
femoropopliteal bypass, with the distal anastomosis
above the knee (AK), there is still controversy as to
whether prosthetic materials like polytetrafluoroethy-
lene (PTFE), Dacron and the human umbilical vein are
equivalent to the autologous saphenous vein.3 How-
ever, prosthetic bypass material may be needed if the
saphenous vein is absent or not suitable for bypass
grafting. Many authors have reported that the patency
of PTFE is similar to that of the autologous vein, and
thus synthetic prostheses are considered to be accep-
table alternatives.4,5
The best evidence that one treatment is superior to
another comes from randomized controlled trials
(RCT). However, very few studies of vein versus
PTFE grafts have been performed, and all had
insufficient power to either prove or reject the
hypothesis that vein is superior to PTFE. Several
non-controlled studies have been performed but most
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of them were historical patient series with a non-
controlled and non-randomized design. Moreover,
different definitions of endpoints and outcomes of
the bypass grafts were used. Since there are several
reports on bypass operations above the knee, we
performed a systematic review of the available studies
reported in the literature to test the hypothesis of the
equivalence of vein grafts and synthetic prostheses as
infrainguinal bypasses for arterial disease in the
above-knee position.
Methods
English and German medical literature from 1966–
2002 was searched using MEDLINE, with the follow-
ing keywords: vascular, vascular patency, vascular
disease, arterial occlusive disease, intermittent claudi-
cation, popliteal artery, blood vessel prosthesis, saphe-
nous vein, and PTFE. All abstracts of the retrieved
articles were reviewed.
The entire article was selected if it fulfilled the
following selection criteria: (i) Follow-up of at least 2
years. (ii) Original study (series that contained
duplicate material was excluded and those series
with the best-documented material were included for
analysis). (iii) Objective proof of patency of the bypass
by duplex evaluation, arteriography, or Doppler
ankle/arm pressure measurements, either alone or in
combination; follow-up by simple palpation of the
pulses of the bypass or the distal arteries was not
considered sufficient.6 (iv) Separate analysis of
patency for the venous and prosthetic bypasses. (v)
Distal anastomosis with the above-knee popliteal
artery. Patency was defined and documented accord-
ing to the requirements published by the Ad Hoc
Committee on Reporting Standards. Primary patency
was defined as uninterrupted patency with no
procedure performed on the bypass graft. Secondary
patency was the patency after restoring an occlusion or
after a procedure to protect the bypass from occluding.
Both reversed vein grafts and in situ vein grafts were
considered as vein grafts.7,8 Exclusion criteria were (i)
the use of composite grafts that consisted of any
combination of vein and prosthesis (including venous
cuffs); (ii) the use of sequential grafts, grafts of arm
veins; and (iii) articles reporting only on secondary
interventions in femoropopliteal bypass grafts.9 The
following baseline characteristics were recorded:
smoking, diabetes mellitus (type I and II), sex, and
age. The indication for bypass surgery was either
claudication or critical ischaemia (as defined by ulcers,
ischaemic rest pain, limb-threatening ischaemia, or
gangrene). Postoperative complications were
recorded. Postoperative mortality was defined as 30-
day mortality, and the number of wound infections
was recorded. During follow-up, all-cause mortality
was documented as well as the amputation rate.
Finally, prescriptions for postoperative anticoagula-
tion therapy or antiplatelet therapy were noted.
Primary patency rates weighted for sample size
were calculated for each interval and stratified by graft
material. Weighted means were also calculated for the
mean age, proportion of male patients, proportion of
smokers, proportion of patients with diabetes, and
proportion of patients with critical ischaemia.
Since we did not collect the primary data of all the
studies, we could not perform a statistical comparison
of the patency rates for vein and PTFE. We therefore
used a non-parametric test, the sign test (which is
simply the binomial test with p ¼ 0:5), as an appro-
priate alternative to test whether the results of the
studies comparing vein with PTFE are consistent with
the null hypothesis (i.e., no difference in patency rates
between vein and PTFE).10
Results
The Medline search retrieved 824 articles on infra-
inguinal bypasses. After the abstract was screened for
the exclusion criteria, 713 articles were excluded. The
main reasons for exclusion were distal anastomosis of
the bypass to the infrainguinal or tibial arteries, the use
of composite grafts, or the article did not report
original research but was either a review or a
comment. Thus 111 studies were selected for further
review.
On the basis of the same inclusion and exclusion
criteria, another 86 articles were excluded. Finally, 25
articles that fulfilled all the inclusion and exclusion
criteria were used (Table 1). Only a minority of these
articles presented data as recommended by the Ad
Hoc Committee on Reporting Standards and included
a complete life table. Most studies, in particular the
non-randomized ones, presented a graphical analysis
rather than numerical data. If life tables were not
available, the patency rates at the various postopera-
tive time intervals were determined from the graphs.
The 25 studies reported a total number of 3804
patients. There were 1284 patients with venous bypasses
and 2520 with PTFE bypasses. Seven randomized and
historical trials compared vein with PTFE and had a
follow-up of at least 5 years; 1026 and 745 patients were
included, respectively.11–17 There were six RCT compar-
ing vein with PTFE and human umbilical vein or
Dacron. These trials included 429 patients with vein
grafts and 643 with PTFE prostheses.11,15,17–20 Four of
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these six prospectively randomized studies exclusively
compared vein grafts (429 bypasses) with PTFE pros-
theses (475 bypasses).11,15,17,20
The patency of venous bypasses was better than
for PTFE bypasses at all time intervals studied.
After 2 years, the primary patency for the venous
bypasses was 81% as compared to 67% for the PTFE
bypasses. In both groups, bypass patency decreased
gradually with time, but this decrease was less
pronounced for vein grafts than for PTFE. After 5
years, the patency of the venous and PTFE bypasses
was 69 and 49%, respectively. After the first year,
the difference in patency between the two graft
materials was 5%. This difference increased to about
14% after 2 years and to 20% after 5 years (Fig. 1).
Similar results were obtained when only random-
ized trials were considered. Again, vein grafts were
superior to PTFE at all time intervals. After 2 years the
patency of venous and PTFE bypasses was 80 and
69%, respectively. After 5 years, it was 74 and 39%,
respectively (Fig. 2).
Only three articles reported the secondary patency
of venous bypasses.11,13,20 The secondary patency for
venous bypasses in these three articles was 77% after 2
years and 65% after 5 years. For PTFE bypasses it was
75 and 60%, respectively, and it was reported in more
articles (Fig. 3).11,13,18 – 29
The baseline characteristics are listed in Table 2.
There were more smokers in the venous bypass group
and more diabetic patients in the PTFE bypass group.
Critical ischaemia was present more often in the PTFE
group. Sex and age were equally distributed between
both the vein and the PTFE groups.
Postoperative mortality was reported in 18 articles
and was shown to be 2.2% overall. For patients with a
venous bypass it was 1.1% (range 0–5)15 – 17,20,30,31 and
for patients with a PTFE bypass it was 2.5% (range 0–
4.7).5,15 – 17,21 – 23,25 – 30,32 – 34 Information on postopera-
tive wound infection was available in 12 articles. In the
venous bypass group the average postoperative
wound infection rate was 5.3% (range 0–9.3),5,15,20,22,
23,25,28 – 30,34 and in the PTFE bypass group it was 4.6%
(range 0–6.1).15,20,21,31 Because of missing and/or
inconsistent data, the amputation rate, the long-term
mortality, and the effect of postoperative anticoagula-
tion therapy could not be analysed reliably.
Table 1. All included articles, meeting the in- and exclusion criteria
Author Journal Year Material Randomized
Aalders (21) J Vasc Surg 1992 PTFE vs. HUV/Dacron þ
Abbot (7) J Vasc Surg 1997 PTFE vs. HUV/Dacron þ
AbuRahma (14) Surgery 1999 PTFE vs. Vein þ
Acherman (15) Swiss Surg 1998 PTFE/Vein 2
Allen (23) Ann Vasc Surg 1996 PTFE 2
Archie (24) Ann Vasc Surg 1994 PTFE/Vein 2
Berlakovich (16)16 Arch Surg 1994 PTFE/Vein 2
Buchbinder (34)(*) Ann Vasc Surg 1989 Vein 2
Burger (22) J Vasc Surg 2000 PTFE vs. Vein þ
Davies (25) Ann Vasc Surg 1991 PTFE 2
Evans (26) Surgery 1981 PTFE 2
Gupta (27) J Vasc Surg 1991 PTFE 2
Harris (28) Aust N Z J Surg 1985 PTFE 2
John (17) Ann R C Surg Eng 1993 PTFE/Vein 2
Johnson (18)(#) J Vasc Surg 2000 PTFE vs. Vein þ
Kavanagh (29) Ir J Med Sc 1998 PTFE 2
Kent (19) Arch Surg 1988 PTFE/Vein 2
O’Donnell (35) Surgery 1983 PTFE 2
Patterson (30) Ann Vasc Surg 1990 PTFE 2
Plecha (31) Cardiovasc Surg 1996 PTFE 2
Quinones-Baldrich (4) J Vasc Surg 1992 PTFE 2
Rosenthal (5) J Cardiovasc Surg 1990 PTFE 2
Stonebridge (32) J Vasc Surg 1997 PTFE 2
Veith (20) J Vasc Surg 1986 PTFE vs. Vein þ
Woratyla (33) Am J Surg 1997 PTFE 2
Fig. 1. Weighted mean primary patency rates for all included
studies using vein grafts compared with those using PTFE
grafts for above knee femoropopliteal bypass.
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Discussion
For many years it has been debated as to whether
PTFE and saphenous vein grafts have a similar
patency for above-knee femoropopliteal bypasses.
While authors agree that only a randomized controlled
trial can definitely resolve this issue, to have adequate
power (80) and significance (0.05) such a study would
need to include about 300 bypasses in each arm. So far,
such a randomized controlled trial has not yet been
performed. Four smaller RCT comparing vein grafts
and PTFE prostheses have been performed, but they
were too small to draw firm conclusions.11,15,17,20 For
this reason, we performed this systematic review.
None of the studies showed PTFE to be superior or
even equivalent to saphenous vein as graft material for
above-knee femoropopliteal bypasses. The mean
difference in 5-year patency was 20%, which is
clinically relevant. Indeed, a significant difference in
patency was already observed after 2 years (a mean
difference of 14%). Since all seven randomized and
non-randomized studies comparing saphenous vein
grafts and PTFE demonstrated the superiority of
saphenous vein grafts, the null hypothesis that there
is no difference between the two types of graft material
was rejected ðp ¼ 0:008Þ: When only RCT were
considered, which provide level I evidence, saphenous
vein grafts were clearly superior to PTFE. Secondary
patency appeared to be similar for the two graft
materials; however, only a few articles reported the
secondary patency of venous bypasses.
Discussion about the patency of PTFE and venous
bypasses is not new. Michaels also did not find
evidence that prosthetic grafts, including PTFE, had
a better patency than vein grafts in his review on
materials for above-knee femoropopliteal bypass
grafts in 1989. He concluded that there was an
advantage in using vein for above-knee bypass
grafting.35 One of his most important conclusions
was that he had statistical difficulties drawing con-
clusions from insufficient data. Twelve years later, this
conclusion is still valid. However, the report of three
randomized studies have been published, which make
our conclusions stronger.11,15,20
Mamody stated in his Cochrane review that it is
tempting to conclude that autologous vein is better
than PTFE, but his results did not firmly support this
conclusion.36 He suggested that a good randomized
controlled trial with a standardization of definitions
was required. In this article, we clearly show that PTFE
bypasses are not equal to venous bypasses. We
therefore think that it is no longer necessary to perform
a randomized controlled trial, especially in view of the
large number of patients that need to be recruited.
After the inclusion period of this review one RCT
comparing vein and PTFE was published in 2003
which found a statistically better patency rate for vein,
which only strengthens our conclusion.37
Since our systematic review included all reports
and not only RCT, there are differences in risk factors
between the groups of patients who underwent
reconstruction with a vein and those with PTFE. We
also combined studies with various designs. Differ-
ences between studies were observed in inclusion
criteria, follow-up methods, and the reporting of risk
factors. Moreover, information on some character-
istics, such as postoperative anticoagulant prescription
could not be analysed, as this information was missing
in most of the studies. Studies of PTFE grafts generally
included a higher proportion of diabetic patients and
patients with critical ischaemia; this might have
caused a lower patency. However, both Aalders
et al.18 (16% diabetics; 16% severe ischaemia) and
Rosenthal et al.27 (26% diabetics; 0% critical ischaemia)
Fig. 2. Weighted mean primary patency rates for all
randomized controlled trials comparing vein with PTFE
grafts for above knee femoropopliteal bypass.
Fig. 3. Weighted mean secondary patency rates for all
included studies using vein grafts compared with those
using PTFE grafts for above knee femoropopliteal bypass.
Table 2. Demographic data of all included articles
Vein PTFE
Smoking 87.7% N ¼ 474 65.2% N ¼ 1771
Diabetes 26.5% N ¼ 914 37.1% N ¼ 2130
Male 67.2% N ¼ 1155 66.2% N ¼ 1729
Severe ischemia 55% N ¼ 974 61% N ¼ 2269
Average age 65.6 years N ¼ 1284 66.0 years N ¼ 2401
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also reported a low 5-year patency (39 and 52%,
respectively). None of the eight trials comparing vein
grafts with PTFE showed diabetes mellitus to affect
patency.11 – 17,20 Three of these trials found no differ-
ence in patency between the two types of grafts in
patients with claudication or critical ischaemia,12,13,15
three did not report on differences,14,17,20 and two only
included patients with claudication.11,15
Because more smokers received saphenous vein
grafts than PTFE grafts, the difference in patency
might be caused by a lower survival of patients
treated with vein grafts. However, both Johnson
et al.15 (98% smokers) and Patterson et al.25 (85%
smokers) showed similar 5-year patency rates (39
and 54%, respectively) to other PTFE studies. None
of the eight trials comparing vein grafts with PTFE
grafts reported smoking to affect patency.11,12 – 17,20
Therefore, differences in the distribution of risk
factors are unlikely to explain the better patency of
vein grafts over PTFE grafts.
Postoperative mortality was lower for saphenous
vein grafts than for PTFE grafts, but the difference
was very small. It could not be explained by
differences in baseline characteristics. This small
difference would not constitute a clinically relevant
argument to favour saphenous vein grafts.
Wound infections occurred more frequently in
patients with a venous bypass, but again this
difference was very small. It could be explained
by the larger wounds required for excision of the
vein and the longer operation time. However, the
difference was not so large that PTFE should be
preferred, especially when bearing in mind the
superior patency of vein grafts.
It would not be expected to perceive a difference in
long-term mortality because the two patient groups
were of the same age. Strikingly, there was a difference
in favour of vein grafts. Differences in demographic
data could not explain this difference because age and
sex were equally distributed among the two patient
groups. There was, however, a difference in follow-up
time, which was longer in the PTFE group. Patients
who receive infrainguinal bypasses generally have
widespread occlusive arterial disease, especially of the
coronary and cerebrovascular arteries, so a longer
follow-up for patients with PTFE grafts may cause the
observed higher mortality among patients with PTFE
grafts. Conclusions on the type of graft and the long-
term amputation rate and postoperative anticoagula-
tion therapy could not be drawn because of missing
and/or inconsistent data.
Conclusions
This systematic review shows that the saphenous vein
is superior to PTFE at all time intervals studied, with a
primary patency at 5 years of 69% compared with 49%,
respectively. Since all seven randomized and non-
randomized studies comparing vein with PTFE
demonstrated vein grafts to be advantageous, the
null hypothesis that there is no difference between the
two types of graft material is rejected ðp ¼ 0:008Þ: More
strikingly, if only the four RCT were considered,
providing level I evidence, the difference in patency
for venous and PTFE bypasses was even greater, 74
and 39%, respectively. After 2 years the difference in
patency for venous and PTFE bypasses was 81 and
67%; in the randomized controlled trial it was 80 and
69%, respectively.
We have convincingly demonstrated that if the
saphenous vein is available, a venous bypass should
be chosen, even for patients with a short anticipated
life expectancy (,2 years). When the saphenous vein
is absent or not suitable for bypass grafting, PTFE is a
good alternative for bypass material.
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